Amneal launches generic lidocaine ointment
BRIDGEWATER, N.J. — Amneal Pharmaceuticals this week launched a new lidocaine product line with the availability of its lidocaine 5% ointment. The company said that it hopes to expand the line with a transdermal patch formulation, which is currently waiting for final approval from the Food and Drug Administration.
“Lidocaine ointment is our third topical medication and, once approved, the patch will be our first transdermal product,” Amneal’s EVP sales and marketing Jim Luce said. “These two additions to our portfolio demonstrate our commitment to expand into new, more complex dosage forms valued by our pharmacy customers and their patients.”
The annual sales for lidocaine ointment in the United States were $251 million for the year ending September 2015, according to IMS Health data. The cream will be available in a 50-g jar and a 35.44-g tube with a child-resistant cap.
Teva launches generic Actiq
BY DSN STAFF
NORTH WALES, Pa. — Teva Pharmaceuticals on Wednesday announced the launch of its new generic of Actiq (fentanyl citrate) oral transmucosal lozenges.
The lozenges are indicated to manage breakthrough pain in cancer patients 16 years old and older who are currently receiving and tolerating around-the-clock opioid medicine. They are contraindicated in patients who are not tolerant of opioids, management of acute or postoperative pain and patients sensitive to any of the drug’s ingredients.
Teva’s lozenges will be available in 200-, 400-, 600-, 800-, 1200-, and 1600-mcg dosage strengths.
Loading Post Please Wait...